Overview

A Study of Epacadostat and Nivolumab in Combination With Immune Therapies in Subjects With Advanced or Metastatic Malignancies (ECHO-208)

Status:
Completed

Trial end date:
2021-01-29

Target enrollment:

Participant gender:

Summary

The purpose of this study is to determine the safety, tolerability, and efficacy of epacadostat when given in combination with nivolumab and ipilimumab, and in combination with nivolumab and lirilumab, in subjects with advanced or metastatic malignancies.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

Incyte Corporation

Treatments:

Antibodies, Monoclonal
Ipilimumab
Nivolumab